SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a Healthcare company (Biotechnology) with a market capitalization of $4.2B. The Maz Rating grades it against the other companies in its sector.
SELLAS Life Sciences Group, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $20.71, SELLAS Life Sciences Group, Inc. trades at 11.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -31.9%, return on invested capital of -29.8% and a free cash flow yield of -1.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 14.92. Over the past 52 weeks the share price ranged from $1.39 to $24.89, with a beta of 2.70.
SELLAS Life Sciences Group, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.